Table 4 Antibiotics used for empiric and definitive therapy among the patients
Variable | Frequency | Percentage (%) |
|---|---|---|
Active empiric therapy | 31 | 28.2 |
Empiric antibiotics used (n = 129) | ||
Piperacillin–tazobactam | 29 | 23.6 |
Ceftriaxone | 15 | 12.2 |
Cefuroxime | 13 | 10.6 |
Meropenem | 12 | 9.8 |
Ampicillin-sulbactam | 12 | 9.8 |
Ciprofloxacin | 8 | 6.5 |
Amoxicillin-clavulanate | 6 | 4.9 |
Metronidazole | 6 | 4.9 |
Ceftazidime | 4 | 3.3 |
Vancomycin | 4 | 3.3 |
Cefoperazone | 4 | 3.3 |
Azithromycin | 4 | 3.3 |
Imipenem | 2 | 1.6 |
Trimethoprim/sulfamethoxazole | 2 | 1.6 |
Clindamycin | 1 | 0.8 |
Cefepime | 1 | 0.8 |
Combination empiric therapy | 15 | 13.6 |
Definitive antibiotics (n = 92) | ||
Meropenem | 74 | 80.4 |
Imipenem | 9 | 9.8 |
Ciproflocaxin | 4 | 4.3 |
Piperacillin–tazobactam | 3 | 3.3 |
Trimethoprim/sulfamethoxazole | 1 | 1.1 |
Ertapenem | 1 | 1.1 |
Combination definitive therapy | 6 | 5.5 |
Mean duration before active antibiotics | 3.9 ± 2.7 | |